Glipizide ER
Name: Glipizide ER
- Glipizide ER glipizide er dosage
- Glipizide ER 5 mg
- Glipizide ER tablet
- Glipizide ER drug
- Glipizide ER mg
- Glipizide ER mg tablet
- Glipizide ER when to take
- Glipizide ER 5 mg tablet
- Glipizide ER side effects
- Glipizide ER serious side effects
- Glipizide ER effects of
Glipizide ER Dosage and Administration
2.1 Recommended Dosing
Glipizide extended-release tablets should be administered orally with breakfast or the first main meal of the day.
The recommended starting dose of glipizide extended-release tablets is 5 mg once daily. Start patients at increased risk for hypoglycemia (e.g. the elderly or patients with hepatic insufficiency) at 2.5 mg [see Use in Specific Population (8.5, 8.6)].
Dosage adjustment can be made based on the patient’s glycemic control. The maximum recommended dose is 20 mg once daily. Patients receiving immediate release glipizide may be switched to glipizide extended-release tablets once daily at the nearest equivalent total daily dose.
2.2 Use with Other Glucose Lowering Agents
When adding glipizide extended-release tablets to other anti-diabetic drugs, initiate glipizide extended-release tablets at 5 mg once daily. Start patients at increased risk for hypoglycemia at a lower dose.
When colesevelam is coadministered with Glipizide ER, maximum plasma concentration and total exposure to glipizide is reduced. Therefore, glipizide extended-release tablets should be administered at least 4 hours prior to colesevelam.
Dosage Forms and Strengths
Glipizide extended-release tablets are supplied as 2.5 mg, 5 mg, and 10 mg round, film-coated tablets and are printed with black ink as follows:
2.5 mg tablets are light orange and printed with “WPI” and “900”.
5 mg tablets are orange and printed with “WPI” and “844”.
10 mg tablets are white to off-white and printed with “WPI” and “845”.
Contraindications
Glipizide is contraindicated in patients with:
- Known hypersensitivity to glipizide or any of the product’s ingredients.
- Hypersensitivity to sulfonamide derivatives.
Patient Counseling Information
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Inform patients of the potential adverse reactions of glipizide extended-release tablets including hypoglycemia. Explain the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development to patients and responsible family members. Also inform patients about the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of glycemic control.
Inform patients that glipizide extended-release tablets should be swallowed whole. Inform patients that they should not chew, divide or crush tablets and they may occasionally notice in their stool something that looks like a tablet. In the glipizide extended-release tablet, the medication is contained within a non-dissolvable shell that has been specially designed to slowly release the drug so the body can absorb it.
Advise patients with diabetes to inform their healthcare provider if they are pregnant, contemplating pregnancy, breastfeeding, or contemplating breastfeeding.
This product’s label may have been updated. For full prescribing information, please visit www.actavis.com.
Brands listed are the trademarks of their respective owners.
Manufactured by:
Patheon Pharmaceuticals Inc.
Cincinnati, OH 45237 USA
Distributed by:
Actavis Pharma, Inc.
Parsippany, NJ 07054 USA
Revised: August 2017
PATIENT INFORMATION Glipizide (glip´ i zide) Extended-Release Tablets |
What are glipizide extended-release tablets?
|
Who should not take glipizide extended-release tablets? Do not use glipizide extended-release tablets if you:
|
What should I tell my doctor before taking glipizide extended-release tablets? Before you take glipizide extended-release tablets, tell your healthcare provider if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Glipizide extended-release tablets may affect the way other medicines work, and other medicines may affect how glipizide extended-release tablets work. Some medicines can affect how well glipizide extended-release tablets work or may affect your blood sugar level. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. |
How should I take glipizide extended-release tablets?
|
What should I avoid while taking glipizide extended-release tablets?
|
What are the possible side effects of glipizide extended-release tablets? Glipizide extended-release tablets can cause serious side effects, including:
If you have signs or symptoms of low blood sugar, eat or drink something with sugar in it right away. If you do not feel better or your blood sugar level does not go up, call your healthcare provider or go to the nearest emergency room. The most common side effects of glipizide extended-release tablets include: dizziness, diarrhea, nervousness, tremor, and gas. These are not all the possible side effects of glipizide extended-release tablets. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How to store glipizide extended-release tablets?
Keep glipizide extended-release tablets and all medicines out of reach of children. |
General information about the safe and effective use of glipizide extended-release tablets. Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use glipizide extended-release tablets for a condition for which it was not prescribed. Do not give glipizide extended-release tablets to other people, even if they have the same symptoms you have. It may harm them. This Patient Information summarizes the most important information about glipizide extended-release tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about glipizide extended-release tablets that is written for healthcare professionals. For more information about glipizide extended-release tablets, you can visit the Actavis internet site at www.actavis.com. |
What are the ingredients in glipizide extended-release tablets? Active ingredient: glipizide Inactive ingredients: acetyltributyl citrate, ammonia, butyl alcohol, edible black ink, ferrosoferric oxide, hydroxyethyl cellulose, hydroxypropyl cellulose, isopropyl alcohol, lactose monohydrate, magnesium stearate, methacrylic acid copolymer type A, polyethylene glycol, propylene glycol and shellac. The 2.5 mg and 5 mg tablets also contain FD&C Yellow #6. Manufactured by: Distributed by: |
This Patient Information has been approved by the U.S. Food and Drug Administration Revised: August 2017